Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations

International Journal of Molecular Medicine

Volumn 20, Issue 5, 2007, Pages 731-741

  Sousa, Hugo ^a,b   Santos, Alexandra M ^a   Pinto, Daniela ^a   Medeiros, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cervical cancer; Geographical location; HPV E6; Human papillomavirus; p53 codon 72 polymorphism

Indexed keywords

PROTEASOME; PROTEIN P53; TUMOR MARKER; UBIQUITIN;

ARTICLE; CAUCASIAN; CODON; CONFIDENCE INTERVAL; EUROPE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; INCIDENCE; META ANALYSIS; METABOLISM; RISK; UTERINE CERVIX TUMOR;

CODON; CONFIDENCE INTERVALS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INCIDENCE; ODDS RATIO; POLYMORPHISM, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UTERINE CERVICAL NEOPLASMS;

EID: 38449109353     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Sankaranarayanan R and Ferlay J: Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20: 207-225, 2006.
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802, 1995.
3. Bosch FX and Munoz N: The viral etiology of cervical cancer. Virus Res 89: 183-190, 2002.
4. Bosch FX and de Sanjose S: Human papillomavirus in cervical cancer. Curr Oncol Rep 4: 175-183, 2002.
5. Castellsague X, Bosch FX and Munoz N: Environmental co-factors in HPV carcinogenesis. Virus Res 89: 191-199, 2002.
6. Franco EL, Rohan TE and Villa LL: Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91: 506-511, 1999.
7. Matos A, Moutinho J, Pinto D and Medeiros R: The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population. Eur J Cancer Prev 14: 485-491, 2005.
8. Moreno V, Munoz N, Bosch FX, de Sanjose S, Gonzalez LC, Tafur L, Gili M, Izarzugaza I, Navarro C and Vergara A: Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 4: 459-467, 1995.
9. Bosch FX, Munoz N, de Sanjose S, Navarro C, Moreo P, Ascunce N, Gonzalez LC, Tafur L, Gili M and Larranaga I: Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 2: 415-422, 1993.
10. Cannistra SA and Niloff JM: Cancer of the uterine cervix. N Engl J Med 334: 1030-1038, 1996.
11. Cooper B, Schneider S, Bohl J, Jiang Y, Beaudet A and Vande PS: Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology 306: 87-99, 2003.
12. Nuber U, Schwarz SE and Scheffner M: The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur J Biochem 254: 643-649, 1998.
13. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
14. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillo-mavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
15. Scheffner M, Huibregtse JM, Vierstra RD and Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505, 1993.
16. Scheffner M: Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 78: 129-139, 1998.
17. Scheffner M and Whitaker NJ: Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 13: 59-67, 2003.
18. Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, Pereira D, Moutinho J, Canedo P, Machado JC and Medeiros R: G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 334: 588-592, 2005. (Pubitemid 40982407)
19. Medeiros RM, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Ferreira P and Lopes C: Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu- Asp298 polymorphism at exon 7. Clin Cancer Res 8: 3433-3437, 2002.
20. Pinto D, Vasconcelos A, Costa S, Pereira D, Rodrigues H, Lopes C and Medeiros R: HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 13: 177-181, 2004.
21. Sousa H, Santos AM, Catarino R, Pinto D, Vasconcelos A, Lopes C, Breda E and Medeiros R: Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. Eur J Cancer Prev 15: 362-366, 2006.
22. Zusman I, Vol A and Kozlenko M: Polymorphism of cellular physicochemical features and cancer: a review. In Vivo 14: 683-689, 2000.
23. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J and Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963, 1987.
24. Sun Y, Keshava C, Sharp DS, Weston A and McCanlies EC: DNA sequence variants of p53: Cancer and aging. Am J Hum Genet 65: 1779-1782, 1999.
25. Dumont P, Leu JI, Della PA III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
26. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004.
27. Jee SH, Won SY, Yun JE, Lee JE, Park JS and Ji SS: Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 85: 301-308, 2004.
28. Koushik A, Platt RW and Franco EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13: 11-22, 2004.
29. Santos AM, Sousa H, Catarino R, Pinto D, Pereira D, Vasconcelos A, Matos A, Lopes C and Medeiros R: TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 159: 143-147, 2005. (Pubitemid 40719383)
30. Chen WC, Tsai FJ, Wu JY, Wu HC, Lu HF and Li CW: Distributions of p53 codon 72 polymorphism in bladder cancer - proline form is prominent in invasive tumor. Urol Res 28: 293-296, 2000.
31. Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179: 175-183, 2002.
32. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L and Beckman G: P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16: 1461-1464, 1995.
33. Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
34. Santos AM, Sousa H, Pinto D, Portela C, Pereira D, Catarino R, Duarte I, Lopes C and Medeiros R: Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 42: 958-963, 2006.
35. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK and Christiani DC: The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9: 1037-1042, 2000.
36. Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF Jr, Herrero R, Bratti MC, Schwartz P, Mortel R, Barnes W, Greenberg M, McGowan L, Scott DR, Martin M, Herrera JE and Carrington M: p53 polymorphism and risk of cervical cancer. Nature 396: 531-532, 1998.
37. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and Banks L: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234, 1998.
38. Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A and Zehbe I: The role of TP53 in cervical carcinogenesis. Hum Mutat 21: 307-312, 2003.
39. Zehbe I, Voglino G, Wilander E, Genta F and Tommasino M: Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 354: 218-219, 1999. (Pubitemid 29329163)
40. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA and Jacobs IJ: p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352: 871-872, 1998. (Pubitemid 28416721)
41. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A and Beckman L: Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270, 1994.
42. de la Calle-Martin O, Fabregat V, Romero M, Soler J, Vives J and Yague J: AccII polymorphism of the p53 gene. Nucleic Acids Res 18: 4963, 1990.
43. Inserra P, Abrahamsen M, Papenfuss M and Giuliano AR: Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int J STD AIDS 14: 800-804, 2003.
44. rbel-Alon S, Menczer J, Feldman N, Glezerman M, Yeremin L and Friedman E: Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. Int J Gynecol Cancer 12: 741-744, 2002.
45. Sjalander A, Birgander R, Kivela A and Beckman G: p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45: 144-149, 1995.
46. Sjalander A, Birgander R, Saha N, Beckman L and Beckman G: p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 46: 41-48, 1994.
47. Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC and Caporaso NE: Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1: 481-483, 1992.
48. Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A and Bontis JN: p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev 9: 113-118, 2002.
49. Dokianakis DN and Spandidos DA: P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. Mol Cell Biol Res Commun 3: 111-114, 2000.
50. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S and Tommasino M: p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 61: 608-611, 2001.
51. Cenci M, French D, Pisani T, Alderisio M, Lombardi AM, Marchese R, Colelli F and Vecchione A: p53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. Anticancer Res 23: 1385-1387, 2003.
52. Humbey O, Aubin F, Cairey-Remonnay S, Riethmuller D, Pretet JL, Fest T, Seilles E and Mougin C: TP53 polymorphism at exon 4 in Caucasian women from eastern France: lack of correlation with HPV status and grade of cervical precancerous lesions. Eur J Obstet Gynecol Reprod Biol 103: 60-64, 2002.
53. Tenti P, Vesentini N, Rondo SM, Zappatore R, Migliora P, Carnevali L and Ranzani GN: p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev 9: 435-438, 2000.
54. Koushik A, Ghosh A, Duarte-Franco E, Forest P, Voyer H, Matlashewski G, Coutlee F and Franco EL: The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev 29: 307-316, 2005.
55. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, Storey A and Matlashewski G: P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 87: 528-533, 2000.
56. Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, Shrivastava S and Dinshaw K: HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol 86: 157-162, 2002.
57. Menczer J: The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved? Isr Med Assoc J 5: 120-123, 2003.
58. Abba MC, Villaverde LM, Gomez MA, Dulout FN, Laguens MR and Golijow CD: The p53 codon 72 genotypes in HPV infection and cervical disease. Eur J Obstet Gynecol Reprod Biol 109: 63-66, 2003.
59. Baek WK, Cho JW, Suh SI, Suh MH, Shin DH, Cho CH, Lee TS and Cha SD: p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women. J Korean Med Sci 15: 65-67, 2000.
60. Brenna SM, Silva ID, Zeferino LC, Pereira JS, Martinez EZ and Syrjanen KJ: Prognostic value of P53 codon 72 polymorphism in invasive cervical cancer in Brazil. Gynecol Oncol 93: 374-380, 2004.
61. Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, Husain SA and Das BC: Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18- associated cervical and oral cancer in India. Mol Cell Biochem 252: 117-124, 2003.
62. Kim JW, Roh JW, Park NH, Song YS, Kang SB and Lee HP: Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. Am J Obstet Gynecol 184: 55-58, 2001.
63. Kucera E, Tong D, Reinthaller A, Leodolter S, Zeillinger R and Sliutz G: p53 polymorphism at codon 72 - Does it constitute a risk for squamous intraepithelial lesions and invasive cancer of the cervix in Central Europeans? Wien Klin Wochenschr 112: 817-820, 2000.
64. Pegoraro R, Moodley J, Naiker S, Lanning P and Rom L: The p53 codon 72 polymorphism in black South African women and the risk of cervical cancer. Br J Obstet Gynaecol 107: 1164-1165, 2000.
65. Pillai MR, Sreevidya S, Pollock BH, Jayaprakash PG and Herman B: Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. J Cancer Res Clin Oncol 128: 627-631, 2002.
66. Wang NM, Tsai CH, Yeh KT, Chen SJ and Chang JG: p53 codon 72Arg polymorphism is not a risk factor for carcinogenesis in the Chinese. Int J Mol Med 4: 249-252, 1999.
67. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E and Borresen-Dale AL: p53 polymorphism and risk of cervical cancer. Nature 396: 530-531, 1998.
68. Hayes VM, Hofstra RM, Buys CH, Hollema H and van der Zee AG: Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet 352: 1756, 1998.
69. Josefsson AM, Magnusson PK, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami HO and Gyllensten UB: p53 polymorphism and risk of cervical cancer. Nature 396: 531, 1998.
70. Brady CS, Duggan-Keen MF, Davidson JA, Varley JM and Stern PL: Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J Gen Virol 80: 3233-3240, 1999.
71. Giannoudis A, Graham DA, Southern SA and Herrington CS: p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer 83: 66-69, 1999.
72. Klaes R, Ridder R, Schaefer U, Benner A and von Knebel DM: No evidence of p53 allele-specific predisposition in human papillomavirus-associated cervical cancer. J Mol Med 77: 299-302, 1999.
73. Tachezy R, Mikyskova I, Salakova M and Van RM: Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum Genet 105: 564-566, 1999.
74. Bertorelle R, Chieco-Bianchi L and Del MA: Papillomavirus and p53 codon 72 polymorphism. Int J Cancer 82: 616-617, 1999.
75. Szarka K, Veress G, Juhasz A, Konya J, Sapy T, Soos G, Hernadi Z and Gergely L: Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers. Anticancer Res 20: 2161-2167, 2000.
76. Dybikowska A, Dettlaff A, Konopa K and Podhajska A: p53 codon 72 polymorphism in cervical cancer patients and healthy women from Poland. Acta Biochim Pol 47: 1179-1182, 2000.
77. Tong D, Kucera E, Stimpfl M, Kolbl H, Leodolter S and Zeillinger R: Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates. Clin Chem 46: 124-126, 2000.
78. van Dun M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, Helmerhorst TJ, Meijer CJ and Walboomers JM: Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 81: 317-325, 2000.
79. Rezza G, Giuliani M, Garbuglia AR, Serraino D, Cappiello G, Migliore G, Branca M, Benedetto A and Ippolito G: Lack of association between p53 codon-72 polymorphism and squamous intraepithelial lesions in women with, or at risk for, human immunodeficiency virus and/or human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 10: 565-566, 2001.
80. Gustafsson AC, Guo Z, Hu X, Ahmadian A, Brodin B, Nilsson A, Ponten J, Ponten F and Lundeberg J: HPV-related cancer susceptibility and p53 codon 72 polymorphism. Acta Derm Venereol 81: 125-129, 2001.
81. Comar M, Molin GD, Guaschino S and Campello C: p53 at codon 72 polymorphism, human papillomavirus infection and cervical lesions: a cross-sectional study from northeastern Italy. Eur J Obstet Gynecol Reprod Biol 114: 210-214, 2004.